CN Patent

CN102884066A — 8-氟-2-{4-[(甲氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂*并[5,4,3-cd]吲哚-6-酮的盐和多晶型物

Assigned to Pfizer Inc · Expires 2013-01-16 · 13y expired

What this patent protects

本发明涉及8-氟-2-{4-[(甲氨基)甲基]苯基}-1，3，4，5-四氢-6H-氮杂 并[5，4，3-cd]吲哚-6-酮(式I)的新的多晶型形式及其制备方法。此类多晶型形式可以是药物组合物的成分，并且可用于治疗由聚(ADP-核糖)聚合酶活性所介导的哺乳动物疾病病状，包括诸如癌症的疾病病状。

USPTO Abstract

本发明涉及8-氟-2-{4-[(甲氨基)甲基]苯基}-1，3，4，5-四氢-6H-氮杂 并[5，4，3-cd]吲哚-6-酮(式I)的新的多晶型形式及其制备方法。此类多晶型形式可以是药物组合物的成分，并且可用于治疗由聚(ADP-核糖)聚合酶活性所介导的哺乳动物疾病病状，包括诸如癌症的疾病病状。

Drugs covered by this patent

Patent Metadata

Patent number
CN102884066A
Jurisdiction
CN
Classification
—
Expires
2013-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.